398 related articles for article (PubMed ID: 20603455)
1. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease.
Thambisetty M; Simmons A; Velayudhan L; Hye A; Campbell J; Zhang Y; Wahlund LO; Westman E; Kinsey A; Güntert A; Proitsi P; Powell J; Causevic M; Killick R; Lunnon K; Lynham S; Broadstock M; Choudhry F; Howlett DR; Williams RJ; Sharp SI; Mitchelmore C; Tunnard C; Leung R; Foy C; O'Brien D; Breen G; Furney SJ; Ward M; Kloszewska I; Mecocci P; Soininen H; Tsolaki M; Vellas B; Hodges A; Murphy DG; Parkins S; Richardson JC; Resnick SM; Ferrucci L; Wong DF; Zhou Y; Muehlboeck S; Evans A; Francis PT; Spenger C; Lovestone S
Arch Gen Psychiatry; 2010 Jul; 67(7):739-48. PubMed ID: 20603455
[TBL] [Abstract][Full Text] [Related]
2. Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment.
Thambisetty M; An Y; Kinsey A; Koka D; Saleem M; Güntert A; Kraut M; Ferrucci L; Davatzikos C; Lovestone S; Resnick SM
Neuroimage; 2012 Jan; 59(1):212-7. PubMed ID: 21824521
[TBL] [Abstract][Full Text] [Related]
3. Analysis of serum β-amyloid peptides, α2-macroglobulin, complement factor H, and clusterin levels in APP/PS1 transgenic mice during progression of Alzheimer's disease.
Wang D; Di X; Fu L; Li Y; Han X; Wu H; Cai L; Meng X; Jiang C; Kong W; Su W
Neuroreport; 2016 Oct; 27(15):1114-9. PubMed ID: 27541273
[TBL] [Abstract][Full Text] [Related]
4. Plasma clusterin levels and the rs11136000 genotype in individuals with mild cognitive impairment and Alzheimer's disease.
Mullan GM; McEneny J; Fuchs M; McMaster C; Todd S; McGuinness B; Henry M; Passmore AP; Young IS; Johnston JA
Curr Alzheimer Res; 2013 Nov; 10(9):973-8. PubMed ID: 24117116
[TBL] [Abstract][Full Text] [Related]
5. The clinical significance of plasma clusterin and Aβ in the longitudinal follow-up of patients with Alzheimer's disease.
Hsu JL; Lee WJ; Liao YC; Wang SJ; Fuh JL
Alzheimers Res Ther; 2017 Nov; 9(1):91. PubMed ID: 29169407
[TBL] [Abstract][Full Text] [Related]
6. Clusterin Levels in Plasma Predict Cognitive Decline and Progression to Alzheimer's Disease.
Jongbloed W; van Dijk KD; Mulder SD; van de Berg WD; Blankenstein MA; van der Flier W; Veerhuis R
J Alzheimers Dis; 2015; 46(4):1103-10. PubMed ID: 26402636
[TBL] [Abstract][Full Text] [Related]
7. Plasma clusterin and the risk of Alzheimer disease.
Schrijvers EM; Koudstaal PJ; Hofman A; Breteler MM
JAMA; 2011 Apr; 305(13):1322-6. PubMed ID: 21467285
[TBL] [Abstract][Full Text] [Related]
8. Plasma Clusterin as a Potential Link Between Diabetes and Alzheimer Disease.
Ha J; Moon MK; Kim H; Park M; Cho SY; Lee J; Lee JY; Kim E
J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32561922
[TBL] [Abstract][Full Text] [Related]
9. Associations of plasma clusterin and Alzheimer's disease-related MRI markers in adults at mid-life: The CARDIA Brain MRI sub-study.
Haight T; Bryan RN; Meirelles O; Tracy R; Fornage M; Richard M; Nasrallah I; Yaffe K; Jacobs DR; Lewis C; Schreiner P; Sidney S; Davatzikos C; Launer LJ
PLoS One; 2018; 13(1):e0190478. PubMed ID: 29324756
[TBL] [Abstract][Full Text] [Related]
10. ApoA1, ApoJ and ApoE Plasma Levels and Genotype Frequencies in Cerebral Amyloid Angiopathy.
Montañola A; de Retana SF; López-Rueda A; Merino-Zamorano C; Penalba A; Fernández-Álvarez P; Rodríguez-Luna D; Malagelada A; Pujadas F; Montaner J; Hernández-Guillamon M
Neuromolecular Med; 2016 Mar; 18(1):99-108. PubMed ID: 26661731
[TBL] [Abstract][Full Text] [Related]
11. Association of the Alzheimer's disease clusterin risk allele with plasma clusterin concentration.
Schürmann B; Wiese B; Bickel H; Weyerer S; Riedel-Heller SG; Pentzek M; Bachmann C; Williams J; van den Bussche H; Maier W; Jessen F
J Alzheimers Dis; 2011; 25(3):421-4. PubMed ID: 21422520
[TBL] [Abstract][Full Text] [Related]
12. Blood clusterin levels, rs9331888 polymorphism, and the risk of Alzheimer's disease.
Xing YY; Yu JT; Cui WZ; Zhong XL; Wu ZC; Zhang Q; Tan L
J Alzheimers Dis; 2012; 29(3):515-9. PubMed ID: 22258514
[TBL] [Abstract][Full Text] [Related]
13. Peritoneal dialysis reduces amyloid-beta plasma levels in humans and attenuates Alzheimer-associated phenotypes in an APP/PS1 mouse model.
Jin WS; Shen LL; Bu XL; Zhang WW; Chen SH; Huang ZL; Xiong JX; Gao CY; Dong Z; He YN; Hu ZA; Zhou HD; Song W; Zhou XF; Wang YZ; Wang YJ
Acta Neuropathol; 2017 Aug; 134(2):207-220. PubMed ID: 28477083
[TBL] [Abstract][Full Text] [Related]
14. Alzheimer risk variant CLU and brain function during aging.
Thambisetty M; Beason-Held LL; An Y; Kraut M; Nalls M; Hernandez DG; Singleton AB; Zonderman AB; Ferrucci L; Lovestone S; Resnick SM
Biol Psychiatry; 2013 Mar; 73(5):399-405. PubMed ID: 22795969
[TBL] [Abstract][Full Text] [Related]
15. Clusterin contributes to early stage of Alzheimer's disease pathogenesis.
Oh SB; Kim MS; Park S; Son H; Kim SY; Kim MS; Jo DG; Tak E; Lee JY
Brain Pathol; 2019 Mar; 29(2):217-231. PubMed ID: 30295351
[TBL] [Abstract][Full Text] [Related]
16. Gender, apolipoprotein E genotype, and mesial temporal atrophy: 2-year follow-up in patients with stable mild cognitive impairment and with progression from mild cognitive impairment to Alzheimer's disease.
Spampinato MV; Langdon BR; Patrick KE; Parker RO; Collins H; Pravata' E;
Neuroradiology; 2016 Nov; 58(11):1143-1151. PubMed ID: 27590747
[TBL] [Abstract][Full Text] [Related]
17. Monitoring disease progression in mild cognitive impairment: Associations between atrophy patterns, cognition, APOE and amyloid.
Falahati F; Ferreira D; Muehlboeck JS; Eriksdotter M; Simmons A; Wahlund LO; Westman E
Neuroimage Clin; 2017; 16():418-428. PubMed ID: 28879083
[TBL] [Abstract][Full Text] [Related]
18. The role of clusterin in Alzheimer's disease: pathways, pathogenesis, and therapy.
Yu JT; Tan L
Mol Neurobiol; 2012 Apr; 45(2):314-26. PubMed ID: 22274961
[TBL] [Abstract][Full Text] [Related]
19. Clusterin mRNA and protein in Alzheimer's disease.
Baig S; Palmer LE; Owen MJ; Williams J; Kehoe PG; Love S
J Alzheimers Dis; 2012; 28(2):337-44. PubMed ID: 22232000
[TBL] [Abstract][Full Text] [Related]
20. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
